Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States

NEW ALBANY, Ohio--(BUSINESS WIRE)--Oct 2, 2026--

Bayer announced on Friday plans to invest 2.2 billion U.S. dollars in a new pharmaceutical manufacturing site in New Albany, Ohio, U.S. Building on more than seven billion dollars in U.S. pharma R&D and manufacturing spend over the past five years, the project is a central element of Bayer’s long-term growth strategy and commitment to innovation and patient access in its largest pharmaceuticals market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002202241/en/

“Bayer has long seen the United States as a key manufacturing base and innovation hub. This landmark investment underscores our commitment,” said Bayer CEO Bill Anderson. “The new site will be home to manufacturing expertise and a skilled workforce that will strengthen our ability to deliver innovative, high-quality medicines to patients both in the United States and abroad.”

“The United States is a key market for Bayer’s Pharmaceuticals division. This expansion is another important step to grow our pharmaceuticals business and to meet the demand of our customers and patients in the U.S., our fastest-growing pharmaceuticals market, and beyond,” said Sebastian Guth, Global Chief Operating Officer, Bayer Pharmaceuticals and President, Bayer U.S.

Planned site to create highly-skilled jobs and support Ohio’s economic development

Bayer is expected to create around 600 high-value jobs in the New Albany International Business Park and roughly 1,500 construction jobs during the facility’s construction.

The flexible, modular campus is designed to combine drug substance and drug product manufacturing, leverage advanced digital and automation technologies, and support our growing portfolio initially in oncology, cardiovascular and renal care. The first module, dedicated to drug substance manufacturing, is expected to become operational in 2031. A second module for drug product manufacturing is planned to follow in 2034. The new site will complement Bayer’s U.S. pharmaceuticals headquarters in Whippany, New Jersey and its other sites in Pittsburgh, Pennsylvania; Berkeley, California; Cambridge, Massachusetts; Research Triangle Park, North Carolina; and San Diego, California.

“The facility will be a strong strategic addition to our global Product Supply network. As we continue to invest in our existing manufacturing sites around the globe, our planned presence in Ohio will further enhance our ability to serve our markets with greater resilience and reliability,” said Holger Weintritt, Head of Product Supply at Bayer’s Pharmaceuticals division.

The site will also form part of a new U.S. based collaboration ecosystem. The ambition is to connect cutting-edge academic innovation with advanced manufacturing expertise to create a strong ecosystem that supports future-ready pharmaceutical production.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to support efforts to master major challenges presented by a growing and aging global population and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.

Rendering of Bayer's new pharmaceutical manufacturing site in New Albany, Ohio, U.S. Building on more than seven billion dollars in U.S. pharma R&D and manufacturing spend over the past five years, the project is a central element of Bayer’s long-term growth strategy and commitment to innovation and patient access in its largest pharmaceuticals market.

Cornell's president called the alleged gang rape of a student at a fraternity house in 2024 “deeply disturbing” Saturday, said it would weigh on the university for years to come and pledged greater transparency amid mounting outrage over the school’s handling of the case.

In an eight-minute video message to the Cornell community, Michael Kotlikoff described the past week as one of the most difficult in the university’s history and acknowledged troubling questions about the investigations that followed the allegations.

“My heart aches when I think of what she experienced,” Kotlikoff said. “It raises heartbreaking and troubling issues about sexual assault, dehumanization and aspects of party culture, alcohol and drug use.”

Kotlikoff reaffirmed his commitment to supporting an independent review of Cornell's handling of the case called for by New York Gov. Kathy Hochul and said the school's Board of Trustees would announce details next week. He also expressed support for Hochul’s decision to turn the criminal investigation over to the state attorney general.

“I want to acknowledge something that can be difficult for an institution to say,” Kotlikoff said. “We don’t have all the answers, but we are committed to investigating and finding the answers our community deserves.”

Scrutiny has mounted in recent days over Cornell’s response to allegations that the woman was sexually assaulted by multiple fraternity members in 2024. The woman, identified in court documents as Jane Doe, has sued the university and seven former students.

During a student assembly hearing Thursday that gave students an opportunity to voice concerns and discuss proposals to improve Cornell’s response to sexual assault, several speakers called for Kotlikoff’s resignation.

Hochul, asked at a news conference Friday whether she believed Kotlikoff should resign over the university’s handling of the case, declined to take a position, saying she did not yet have enough information.

Kotlikoff acknowledged frustration that Cornell has not communicated enough, saying that has led to distrust. While citing “real legal and privacy limits” on what the university can disclose, he pledged greater transparency and more opportunities for students, parents and others to engage with university leaders.

He also committed Cornell’s support to legislative efforts to change New York’s sexual assault laws.

The case has renewed scrutiny of a state law that makes it difficult to prosecute sexual assaults involving people who voluntarily consume alcohol or drugs, even if they became too intoxicated to consent.

Tompkins County District Attorney Matthew Van Houten cited the law in defending his initial decision not to pursue charges, saying the woman’s original statement to police described voluntary drug use and sexual activity.

Critics have long sought to close what they call the “voluntary intoxication loophole,” which distinguishes between people incapacitated by drugs administered without their consent and those who voluntarily became intoxicated. Hochul has pledged to push for changes to the law.

Kotlikoff also called for a “serious look at the role of fraternities and sororities in campus life,” saying Cornell would engage students, alumni and others in examining how to preserve the benefits of Greek life while strengthening accountability and transparency.

“Being part of a group can never diminish individual responsibility for our own actions, for how we treat others or for speaking up when someone may be at risk,” he said.

Pedestrians walk on the campus at Cornell University in Ithaca, N.Y., Thursday, Oct. 1, 2026. (AP Photo/Matt Rourke)